Drug recall · July 19, 2017
Paliperidone Extended-Release Tablets recall
Why: Failed Dissolution Specifications: Drug release test result, obtained during routine 9-month stability testing, which was below specification for one tablet. Teva cannot at this time exclude the potential for additional tablets to be below specification.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Paliperidone Extended-Release Tablets, 3 mg, 90 count bottles, Rx only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA, NDC: 0591-3693-19
- Lots / codes
Lot: 1160682A, EXP. 06/18
- Quantity
- 360 bottles
- Company
- Teva Pharmaceuticals, Horsham, PA
- Distribution
- Nationwide in the US
- Initiated
- May 31, 2017 · Voluntary: Firm initiated
- Classified
- July 11, 2017
- Reported
- July 19, 2017
- Ended
- March 29, 2018
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Paliperidone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.